Treatment News : PrEP May Reduce Risk of Herpes By a Third

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » July 2014

Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

July 10, 2014

PrEP May Reduce Risk of Herpes By a Third

Pre-exposure prophylaxis (PrEP) to prevent getting HIV may also lower the risk of contracting herpes simplex 2 (HSV-2), MedPage Today reports. Publishing their findings in the Annals of Internal Medicine, researchers conducted a subgroup analysis of a randomized controlled trial of PrEP among heterosexual couples in which one member was HIV positive. None of the participants who were HIV negative at the outset of the study had herpes at that time.

A total of 1,041 of the HIV-negative partners were randomized to receive either tenofovir or Truvada (tenofovir/emtricitabine) as PrEP, while 481 received a placebo. A total of 131 of these participants contracted herpes, including 79 in the PrEP group, for an incidence rate of 5.6 per 100 person years, and 52 in the placebo group, for an incidence rate of 7.7 per 100 person years. Thus, PrEP reduced the chance of acquiring herpes by 30 percent. Out of the 1,044 participants on either PrEP or the placebo who had HSV-2-positive partners, PrEP cut the herpes risk by 33 percent.

Tenofovir has been shown to combat HSV-2 in laboratory experiments, while emtricitabine apparently does not act as such a prophylaxis.

The researchers concluded that “modest protection against HSV-2 is an added benefit of HIV-1 prevention with oral tenofovir-based PrEP.”

To read the MedPage Today story, click here.

To read the study abstract, click here.

Search: PrEP, pre-exposure prophylaxis, herpes simplex 2, HSV-2, Annals of Internal Medicine, Truvada, tenofovir, emtricitabine.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (1 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    adorableone
    New York
    New York


    Reginaldb06
    Dallas
    Texas


    Sexynyrican
    Brooklyn
    New York


    blaze11212
    brooklyn
    New York
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Do you work with your doc to design your own treatment regimen?
Yes
No

Survey
PrEP Course

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.